Streetbeat News

Stock Prices

ALT

Altimmune, Inc. will present new data on the lipidomic profile of subjects treated with pemvidutide at The Liver Meeting 2024. The data shows reductions in atherogenic and cardio-inflammatory lipids from a Phase 1b study. A Phase 2b trial is ongoing with results expected in Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:26 pm

VTYX

Ventyx Biosciences presented 52-week results from their Phase 2 trial of VTX002 (Tamuzimod) for treating ulcerative colitis at UEG Week 2024 in Vienna. This development could impact the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:24 pm

CTLT

HAL

LLY

NVO

UEC

Jim Cramer recommends Uranium Energy Corp. (UEC) due to its acquisition of Rio Tinto's Wyoming assets, while expressing skepticism about Novo Nordisk (NVO) compared to Eli Lilly (LLY). Concerns arise over Novo Nordisk's acquisition of Catalent (CTLT) due to potential antitrust issues. Cramer advises against Halliburton (HAL), despite a Buy rating from BofA Securities.

Portfolio Pulse from Avi Kapoor

October 15, 2024 | 12:22 pm

PEGY

Pineapple Energy Inc. (NASDAQ:PEGY) will implement a 1-for-50 reverse stock split on October 17, 2024, to increase its stock price and maintain Nasdaq listing compliance.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:21 pm

LTH

Life Time Group shares are experiencing an increase in trading value due to better-than-expected preliminary Q3 revenue results.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:21 pm

DJIA

GS

IAI

Goldman Sachs reported strong Q3 earnings with a 7% increase in sales year-over-year, driven by a 20% surge in investment banking fees and a 16% rise in Asset & Wealth Management revenues. However, Fixed Income revenues fell by 12%. The company beat EPS expectations and announced a $3.00 dividend per share. GS shares rose 2.92% premarket.

Portfolio Pulse from Lekha Gupta

October 15, 2024 | 12:20 pm

ANNX

Annexon, Inc. will present new Phase 2 data for ANX007, a treatment for dry AMD, at the American Academy of Ophthalmology 2024 meeting. The data shows significant vision protection and photoreceptor preservation. Phase 3 data is expected in the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:18 pm

CRVO

CervoMed Inc. has completed the last patient visit in its Phase 2b trial of neflamapimod for early-stage dementia with Lewy bodies. The company plans to report topline data in December 2024, with promising potential for cognitive and motor function improvement.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:18 pm

VXRT

Vaxart, Inc. (NASDAQ:VXRT) will present data on its norovirus oral pill vaccine candidate at IDWeek 2024, highlighting its commitment to addressing the unmet need for a norovirus vaccine. Norovirus affects 21 million people annually in the U.S., with significant economic and health impacts.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:16 pm

F

KSS

WHR

Analysts have provided ratings on three consumer stocks with high dividend yields: Kohl's, Whirlpool, and Ford. Kohl's received a downgrade from JP Morgan and a price target cut from Evercore ISI. Whirlpool was rated Underperform by B of A Securities and RBC Capital. Ford was upgraded by Goldman Sachs but downgraded by Morgan Stanley, with an ongoing NHTSA investigation into its Edge SUVs.

Portfolio Pulse from Avi Kapoor

October 15, 2024 | 12:15 pm